Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Haematologica

Volumn 99, Issue 7, 2014, Pages 1184-1190

  Andrikovics, Hajnalka ^a   Krahling, Tunde ^a   Balassa, Katalin ^a   Halm, Gabriella ^b   Bors, Andras ^a   Koszarska, Magdalena ^a   Batai, Arpad ^b   Dolgos, Janos ^b   Csomor, Judit ^b   Egyed, Miklos ^c   Sipos, Andrea ^b   Remenyi, Peter ^b   Tordai, Attila ^a   Masszi, Tamas ^b,d  

^a Hungarian National Blood Transfusion Service   (Hungary)

^b Szent Laszlo Hospital   (Hungary)

^c Kaposi Mor County Hospital   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ALLELE; ARTERY THROMBOSIS; ARTICLE; CALRETICULIN GENE; CHILD; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SOMATIC MUTATION; SPLENOMEGALY; THROMBOCYTE COUNT; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; MYELOPROLIFERATIVE DISORDERS; NUCLEOTIDE SEQUENCE; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CALRETICULIN; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 84903648668     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.107482     Document Type: Article

References (32)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97.
5. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82.
6. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668-76.
7. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356(5):459-68.
8. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-90.
9. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405.
10. Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, et al. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia. 2014;28(5): 1152-4.
11. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10): 1552-5.
12. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-51.
13. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014 Jan 9. doi: 10.1038/leu.2014.3. [Epub ahead of print]
14. Broseus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014;28(6):1374-6.
15. Hou HA, Kuo YY, Chou WC, Chen PH, Tien HF. Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome. Leukemia. 2014 Feb 17. doi: 10.1038/leu.2014.71. [Epub ahead of print]
16. Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol. 2014;89 (4):450.
17. Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014;28(6):1357-60.
18. Patnaik MM, Belachew A, Finke C, Lasho TL, Hanson CA, Tefferi A. CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia. 2014;28(6):1370-1.
19. Andrikovics H, Meggyesi N, Szilvasi A, Tamaska J, Halm G, Lueff S, et al. HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. Cancer Epidemiol Biomarkers Prev. 2009;18(3):929-34.
20. Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, et al. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010;24(10):1809-13.
21. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphiachromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136 (5):745-51.
22. Boyd EM, Bench AJ, Goday-Fernandez A, Anand S, Vaghela KJ, Beer P, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol. 2010;149(2):250-7.
23. Bergamaschi GM, Primignani M, Barosi G, Fabris FM, Villani L, Reati R, et al. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood. 2008;111(8): 4418.
24. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014 Feb 19. doi: 10.1038/leu.2014.76. [Epub ahead of print]
25. Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol. 2014;89(5):453-6.
26. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;89(5):453-6.
27. Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014 Feb 26. doi: 10.1038/leu.2014.83. [Epub ahead of print]
28. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-53.
29. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41-8.
30. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-82.
31. Wang J, Xu Z, Liu L, Gale RP, Cross NC, Jones AV, et al. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia. 2014;27(8):1763-7.
32. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-40.